Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS 2 to the CHA 2 DS 2 -VASc Score for Thromboembolic Risk Assessment

Author:

Katz David F.1,Maddox Thomas M.1,Turakhia Mintu1,Gehi Anil1,O’Brien Emily C.1,Lubitz Steven A.1,Turchin Alexander1,Doros Gheorghe1,Lei Lanyu1,Varosy Paul1,Marzec Lucas1,Hsu Jonathan C.1

Affiliation:

1. From the Section of Cardiac Electrophysiology, Division of Cardiology, University of Colorado School of Medicine, Denver (D.F.K., L.M.); Colorado Cardiovascular Outcomes Research Consortium, Denver (D.F.K., T.M.M., P.V., L.M.); Cardiology Section, VA Eastern Colorado Health Care System, Denver (T.M.M., P.V.); Section of Cardiac Electrophysiology, Division of Cardiology, Palo Alto VA Medical Center and Stanford University School of Medicine, CA (M.T.); Section of Cardiac Electrophysiology, Division...

Abstract

Background— Use of the CHA 2 DS 2 -VASc score instead of the CHADS 2 score for thromboembolic risk stratification and initiation of oral anticoagulation (OAC) was recommended in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society atrial fibrillation (AF) guidelines. We sought to define the proportion of patients with AF qualifying for and receiving OAC in contemporary practice by applying the CHA 2 DS 2 -VASc score to patients with a low CHADS 2 score. Methods and Results— Among patients with AF enrolled in the American College of Cardiology National Cardiovascular Data Registry’s outpatient Practice Innovation and Clinical Excellence registry (2008–2014) CHADS 2 score of 0 or 1, we calculated the impact of adoption of the CHA 2 DS 2 -VASc score on the proportion of patients with an indication for OAC. We examined trends in prescription of OAC overall, direct OAC (dabigatran/rivaroxaban/apixaban), and multivariable associations between clinical characteristics and OAC use. Of 346 068 patients with AF aged 65±12 years, 61% were men and 65% were white. In total, 24% of those with CHADS 2 =0 and 81% of those with a CHADS 2 =1 were reclassified as having a definite indication for OAC (CHA 2 DS 2 -VASc score ≥2). OAC use increased from 37% to 48% during the study period, and direct OAC use increased from 5% to 30%. Increasing CHA 2 DS 2 -VASc score (odds ratio, 2.07; 95% confidence interval, 1.97–2.19 for score of 4 versus 0) and rhythm control strategy (odds ratio, 1.34; 95% confidence interval, 1.30–1.39) were associated with increased OAC use. Conclusions— Adoption of the CHA 2 DS 2 -VASc score reclassifies 64.5% of patients with AF with low CHADS 2 scores into a class I indication for OAC prescription. Overall OAC prescription increased between 2011 and 2014.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3